TScan Therapeutics

TCRX

Market cap $61.3M

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago.

Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2025, and provided business updates.

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 2026 at 11:50 a.m. Eastern Time.

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET.

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.25 per share a year ago.

Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA ™ Phase 1 heme trial to be presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of the heme program and initiate preclinical development of in vivo-engineered TCR-T for solid tumors Cash, cash equivalents, and marketable securities expected to fund operations into the second half of 2027 WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held at the InterContinental Boston in Boston, MA on Wednesday, November 12, 2025 at 10:00 a.m. Eastern Time.

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to focus clinical development on heme program and initiate pre-clinical development of in vivo-engineered TCR-T for solid tumors Strategic prioritization extends cash runway into H2 2027 Conference call and webcast scheduled for Monday, November 3, 8:00 a.m. Eastern Time WALTHAM, Mass.

Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025